Safety and Immunogenicity of Different Formulations of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico: Final Results after 3 Years of Follow-Up from a Randomized, Placebo-Controlled Phase I Study

Four formulations of an investigational tetravalent dengue purified inactivated vaccine, administered as two doses one month (M) apart, were previously shown to be immunogenic and well-tolerated up to M13 of the phase I study NCT01702857. Here, we report results of the follow-up from M14 to year (Y)...

Descripción completa

Detalles Bibliográficos
Autores principales: Diaz, Clemente, Koren, Michael, Lin, Leyi, Martinez, Luis J., Eckels, Kenneth H., Campos, Maribel, Jarman, Richard G., De La Barrera, Rafael, Lepine, Edith, Febo, Irma, Vaughn, David W., Wilson, Todd M., Paris, Robert M., Schmidt, Alexander C., Thomas, Stephen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Tropical Medicine and Hygiene 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204593/
https://www.ncbi.nlm.nih.gov/pubmed/32124728
http://dx.doi.org/10.4269/ajtmh.19-0461

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204593/
https://www.ncbi.nlm.nih.gov/pubmed/32124728
http://dx.doi.org/10.4269/ajtmh.19-0461

Ejemplares similares